Kamya Sankar
Medical Oncology · Los Angeles, CANPI 1346602836
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,460 of the $2,702 with a category attached, or 91.1%. Astrazeneca UK Limited accounts for 91.1% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $2,528, more than ten times the $70 reported in 2022. That places this record below the midpoint for medical oncology clinicians in CA, where the typical reported total is $4,042.
Across 4 payments — averaging $675.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astrazeneca UK Limited$2K
- Galvanize Therapeutics, Inc$104
- Daiichi Sankyo Inc.$70
- Genentech USA, Inc.$68
Across 22 payments — averaging $35,195 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$245K
- AstraZeneca$179K
- Merck$171K
- Eli Lilly$97K
- Amgen$53K
- Janssen Research & Development, LLC$29K
What the payments were for
- Consulting fees$2,46091%
- Food & beverage$2429%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astrazeneca UK Limited | 1 | $2,460 |
| Galvanize Therapeutics, Inc | 1 | $104 |
| Daiichi Sankyo Inc. | 1 | $70 |
| Genentech USA, Inc. | 1 | $68 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TAGRISSO$2,460
- ALIYA SYSTEM$104
How this compares
$2,702 in reported general payments places this provider in the 45th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 23 | $384,175 |
| Imatinib Mesylate | 23 | $2,361 |
| Prochlorperazine Maleate | 14 | $305 |
| Potassium Chloride | 15 | $235 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Los Angeles
- Stephen LiuLos Angeles$750K
- Jacek PinskiLos Angeles$672K
- Mark AgulnikLos Angeles$303K
- Heinz-Josef LenzLos Angeles$185K
- Syma IqbalLos Angeles$178K
- Anthony El-KhoueiryLos Angeles$156K
- David QuinnLos Angeles$134K
- David TranLos Angeles$128K
- Afsaneh BarziLos Angeles$107K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.